FDA Determines Regulatory Review Period for BRIVIACT ORAL TABLETS Patent Extension

Summary

The U.S. Food and Drug Administration (FDA) has officially announced its decision on the regulatory review period for BRIVIACT ORAL TABLETS, a new drug application submitted to the U.S. Patent and Trademark Office (USPTO) in an effort to extend the patent protection for this medication.